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Abstract. Intracapsular and well‑defined adenocarcinomas of 
the prostate are often surrounded by tissue areas that harbor 
molecular aberrations, including those of genetic, epigenetic 
and biochemical nature. This is known as field cancerization, 
or a field effect and denotes a state of pre‑malignancy. Such 
alterations in histologically normal tumor‑adjacent prostatic 
tissues have been recognized as clinically important and 
are potentially exploitable as biomarkers of disease and/or 
targets for preventative/therapeutic intervention. The authors 
have previously identified and validated two protein markers 
of field cancerization: The expressional upregulation of the 
transcription factor early growth response 1 (EGR‑1) and the 
lipogenic enzyme fatty acid synthase (FASN). However, the 
molecular etiology of prostate field cancerization, including 
EGR‑1 and FASN upregulation, remains largely unknown. 
It was thus hypothesized that extracellular vesicles, notably 
exosomes, released by tumor lesions may induce molecular 
alterations in the surrounding tissues, resulting in field 
cancerization, priming the tissue, and ultimately promoting 
multifocal tumorigenesis, which is often observed in prostate 
cancer. Towards testing this hypothesis, the current study, 
to the best of our knowledge, for the first time, presents 
correlative protein expression data, generated in disease‑free, 
tumor‑adjacent and cancerous human prostate tissues by quan-
titative immunofluorescence, between the exosomal marker 
CD9, and EGR‑1 and FASN. Despite the pilot character of 
the present study, and the static nature and heterogeneity of 
human tissues, the data suggest that CD9 expression itself is 
part of a field effect. In support of this hypothesis, the results 
suggest a possible contribution of exosomes to the induction 
of field cancerization in the prostate, particularly for EGR‑1. 
These findings were corroborated in established cell models 
of cancerous (LNCaP) and non‑cancerous (RWPE‑1) human 
prostate epithelial cells. The findings of this study warrant 
further investigation into the functional interface between 
exosomes and field cancerization, as a detailed understanding 
of this characterization may lead to the development of clinical 
applications related to diagnosis and/or prognosis and targeted 
intervention to prevent progression from pre‑malignancy to 
cancer.
Introduction
Since the otolaryngologist Danely Slaughter introduced the 
concept of field cancerization in 1953 in stratified squamous 
epithelia of the oral mucosa of patients suffering from oral 
diseases (1), the definition of this term, also known as the 
field effect, field defect, or field carcinogenesis, has changed 
mainly due to the rapid development of analytical techniques 
in molecular biology and genetics developed over the past 
decades. First, the original intent was to describe the occur-
rence of cancerous cells in histologically normal tissues at 
some distances from the primary lesions, and to explain the 
multifocality of solid tumors, particularly in the case of oral 
cancers, including squamous cell carcinomas (1,2). These 
cells are by definition clinically detectable. By contrast, the 
current definition of field cancerization applies to structur-
ally and phenotypically intact cells residing in histologically 
normal tissues outside the confinement of the primary tumor. 
These cells do not typically distinguish themselves from their 
surrounding and thus remain clinically hidden. The latter 
points to the second major change of the term ‘field canceriza-
tion’, i.e., the shift in focus on the molecular characterization 
of affected cells and tissues, as opposed to their phenotypical 
appearance (3). Consequently, cells that are part of ‘field 
cancerized’ tissues are considered to be molecularly altered in 
the absence of other visually obvious changes. Furthermore, 
the nature of these molecular alterations is typically indicative 
of a positively ‘primed’ or ‘committed’ status with respect to 
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cell proliferation, growth, migration and/or survival, essen-
tially delineating the affected cells as pre‑malignant (4‑6). 
The authors have continuously contributed to the molecular 
characterization of field cancerization in prostate tissues by 
describing both genetic and biochemical deviations from 
normalcy (7‑13). This has included the observation of telomere 
attrition (9), as well as the upregulation of protein expression, 
including the key transcription factor early growth response 1 
(EGR‑1) and the anabolic enzyme fatty acid synthase 
(FASN) (7,11).
Although the importance of field cancerization in repre-
senting a type of pre‑malignancy in tissues that are prone to 
tumorigenesis has been recognized and acknowledged, the 
molecular and cellular mechanisms underpinning its etiology, 
while often discussed, remain largely unknown (4‑6). This is 
also true for field cancerization in prostatic tissues and stands 
in contrast to the growing list of molecular and cellular markers 
describing it (13,14). A recent focus in urological research has 
been the functional role of extracellular vesicles released by 
virtually all types of cells in the prostate as part of inter‑cell 
and inter‑organ compartment communication (15,16). These 
extracellular vesicles include exosomes that have been charac-
terized to be in the range of 30‑150 nanometers in diameter. 
The importance of exosomal function in normal prostate 
physiology has been well recognized and is primarily due to 
their biologically active ‘cargo’ that includes multiple types of 
RNAs, lipids and proteins (17‑20). Conceptually, the biochem-
ical composition of exosomes reflects the current physiology of 
the cell of origin. It is thus not inconceivable to assume that a 
specific physiological signature can be conveyed or transferred 
to recipient cells. This line of thought has led to the hypothesis 
of a potential role of exosome release and action in the etiology 
of field cancerization. The authors have thus begun to test 
this hypothesis by assessing a potential correlation in protein 
expression between the exosomal marker and tetraspanin, 
CD9, and the afore‑mentioned field cancerization markers, 
EGR‑1 and FASN, in human prostate tissues. Cultured cell 
models of prostate cancer were also used to corroborate these 
findings. The results indicate a possible association between 
exosomes and the expression of EGR‑1 and potentially, that of 
FASN in prostate tissues affected by field cancerization. This 
novel insight into pathways underlying prostate field effect 
may lead to the development of targeted intervention strategies 
preventing progression from pre‑malignancy to cancer.
Materials and methods
Tissues and cells. Tissue microarrays (TMAs) were purchased 
from US Biomax, Inc. (https://www.biomax.us/). No human 
tissues from other sources, other than commercially available 
TMAs, were used in the present study. The use of any human 
tissues, including commercially available TMAs, is covered 
by the Chapman University Institutional Review Board (IRB) 
study #1415H024. For the present study, the formalin‑fixed 
and paraffin‑embedded (FFPE) TMA BC 19021a was 
used, featuring 5‑µm‑thick cancerous, tumor‑adjacent and 
disease‑free (normal) human prostate tissue cores of 1.5 mm in 
diameter. Experiments with human tissues was approved by the 
Institutional Review Board of Chapman University. The tissue 
cohort analyzed in this study consisted of 8 adenocarcinomas, 
8 tumor‑adjacent tissues, and 6 disease‑free tissues. These 
were selected for inclusion to represent variation in age and 
tumor stage and based on immunofluorescence quality. The 
matching status of the tumor‑adjacent tissues with the featured 
tumors is unknown. Also unknown was the distance from 
the tumor margin at which adjacent tissues were resected. 
However, a common practice in our own research is resection 
at a distance of approximately 1 cm from the visible tumor 
margin (7‑11,21). The definition of the term ‘disease‑free’ 
refers to prostate specimens from autopsy cases from 
individuals who died due to conditions unrelated to cancer. 
The mean age of all cases utilized was 54.7 years with a range 
of 21‑80 years. The cancer specimens featured Gleason scores 
from 4 to 10 and pathological tumor node metastasis (TNM) 
stages (according to the American Joint Committee on Cancer; 
https://cancerstaging.org/Pages/default.aspx) from T2aN0M0 
to T2N1M1b (Table I).
Non‑cancerous RWPE‑1 and cancerous LNCaP human 
prostate epithelial cells were purchased from the American 
Type Culture Collection (ATCC) and cultured in serum‑free 
keratinocyte basal medium containing 4,500 mg/l glucose, 
0.05 mg/ml bovine pituitary extract and 5 ng/ml recombinant 
epidermal growth factor (EGF) (for RWPE‑1), or in RPMI‑1640 
medium supplemented with 10% heat‑inactivated (56˚C, 1 h) 
fetal bovine serum (FBS) and 100 U/ml penicillin/strep-
tomycin (for LNCaP). Cells were maintained at 37˚C in a 
humidified 5% CO2 atmosphere. Trypsin‑EDTA at 0.25% was 
used to detach the cells for splitting and re‑culturing.
Immunofluorescence. Immunofluorescence was performed 
as described in previous studies by the authors on prostate 
field cancerization (7,10,11). In order to query the same tissue 
areas for the three protein markers under investigation (CD9, 
EGR‑1 and FASN), consecutive sections, each 5 µm apart 
from each other were used (Fig. 1). TMAs were subjected to 
deparaffinization with xylene and rehydrated with decreasing 
concentrations of ethanol. Antigen retrieval was performed in 
boiling 10 mM Tris, 1 mM EDTA, 0.05% Tween‑20, pH 9.0 
(by HCl) for 10 min, washed briefly in tap water, followed by 
gentle agitation in Tris buffered saline (TBS; 50 mM Tris, 
150 mM NaCl, pH 7.6 by HCl) containing 0.025% Triton 
X‑100 (TBST). Tissues were blocked in 10% normal goat 
serum (sc‑2040, Santa Cruz Biotechnology) in TBS containing 
1% bovine serum antigen (BSA) for 2 h at room temperature, 
then incubated with primary antibodies in TBS containing 
1% BSA at 4˚C overnight. These were all mouse mono-
clonal antibodies from Abcam used at 3 µg/ml: Anti‑CD9 
(ab2215), anti‑EGR‑1 (ab55160) and anti‑FASN (ab218306). 
The control antibody to ensure target specificity at the same 
concentration was normal mouse IgG (GC270, Millipore). 
The corresponding secondary antibody, used at a dilution of 
1:750, was Alexa Fluor 594‑conjugated goat anti‑mouse IgG 
(A11005, Life Technologies; Thermo Fisher Scientific; excita-
tion at 590 nm, emission at 618 nm). Nuclear counterstaining 
was performed with diamidino‑2‑phenylindole (DAPI) in TBS 
for 2 min. Fluorescence was preserved using Fluoroshield 
solution (Sigma) under coverslips sealed with nail polish. Cells 
were cultured and prepared for qualitative immunofluores-
cence concomitantly (on the same slide) on Millicell EZ slides 
(Millipore) to ensure equal experimental and thus comparative 
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treatment. The cells were fixed in 4% formaldehyde followed 
by 3 washes in TBS and stained as for the tissues above.
Fluorescence for both cells and tissues was detected 
using an A1R Nikon confocal microscope available at the 
Chapman University School of Pharmacy Microscopy Core 
Facility. For the tissues, fluorescence was quantified using the 
NIS‑Elements AR 4.30.02/64bit software to analyze acquired 
digital images. Consistent with previous studies by the 
authors (7,10,11), the fluorescence signal acquisition mode was 
applied to 2‑10 images per tissue sample. Great care was taken 
in choosing tissue areas with as equal as possible numbers of 
DAPI‑stained nuclei from epithelial compartments to account 
for equal number of cells analyzed. In addition, identical areas 
on the consecutive sections were imaged for the three specific 
protein markers (CD9, EGR‑1 and FASN) to allow the reported 
correlation analyses. For all specific markers, the acquisition 
setting was kept identical for all images taken to ensure the 
validity of intra‑ and inter‑tissue comparisons. The number 
of images amenable to quantitative fluorescence analysis 
per individual tissue and protein marker under investigation 
is indicated in Table I. In total, 336 images with associated 
quantitative immunofluorescence data were available for the 
present analysis.
Isolation of exosomes. Exosomes were isolated from cancerous 
LNCaP and from non‑cancerous RWPE‑1 cells according to 
the Current Protocols in Cell Biology (John Wiley & Sons, 
Inc.) using ultracentrifugation in an Optima XE‑90 ultracen-
trifuge (Beckman Coulter). Cells grown to 80% confluency 
in complete growth medium were washed twice in medium 
Table I. Demographics and clinical parameters of prostate tissues, and the no. of images analyzed.
 No. of images
 --------------------------------------------------------------------------------
Prostate tissues Age, years TNMa Gleason score CD9 EGR‑1 FASN
Disease‑free      
  1 21   6 6 3
  2 21   5 5 5
  3 25 Not applicable  6 10 6
  4 25   6 9 4
  5 27   6 8 5
  6 27   6 10 5
Total    35 48 28
Adjacent      
  1 40   7 8 5
  2 76   6 7 3
  3 73   7 8 7
  4 73 Not available  8 8 7
  5 62   6 9 5
  6 62   6 6 6
  7 72   7 7 7
  8 80   6 7 4
Total    53 60 44
Tumor      
  1 76 T2aN0M0   4 (2+2) 6 6 5
  2 76 T2aN0M0   4 (2+2) 6 6 2
  3 72 T2N0M0   6 (3+3) 7 8 4
  4 72 T2N0M0   6 (3+3) 6 7 5
  5 40 T2N1M1b   9 (5+4) 6 6 6
  6 40 T2N1M1b   9 (5+4) 7 5 5
  7 72 T2N0M1 10 (5+5) 6 6 5
  8 72 T2N0M1 10 (5+5) 5 7 5
Total    49 51 37
A total of 8 adenocarcinomas (tumor), 8 tumor adjacent tissues (adjacent), and 6 disease‑free tissues were analyzed. In total, 336 images were 
queried (numbers for each case and marker are indicated). aTumor nodes netastasis (TNM) pathological stage was assigned using criteria 
published by the American Joint Committee on Cancer (https://cancerstaging.org/Pages/default.aspx). EGR‑1, early growth response 1; FASN, 
fatty acid synthase.
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without serum, then incubated at 37˚C for 48 h in medium 
containing 10% exosome‑free FBS. Exosome‑free FBS was 
prepared by a 2‑h long ultracentrifugation of medium/20% FBS 
at 100,000 x g at 4˚C to pellet exosomes stemming from the 
FBS. Upon collection of the medium from the cells, it was 
subjected to the following sequential centrifugation procedure 
(all steps at 4˚C): i) 300 x g for 10 min to remove live cells; 
ii) 2,000 x g for 10 min to remove dead cells; iii) 10,000 x g for 
30 min to remove cell debris; iv) 100,000 x g for 2 h to pellet 
the exosomes; v) the resulting pellet was washed in phosphate 
buffered saline (PBS) to remove contaminating proteins and 
recentrifuged at 100,000 x g for 2 h to obtain exosomes of high 
purity; vi) the final pellet was resuspended in a small volume 
of PBS, typically 150 µl for an original of 40 ml culture 
supernatant. Exosomes were aliquoted and stored short‑term 
at ‑80˚C with avoidance of multiple freeze‑thaw cycles. The 
amount and viability of cells giving rise to the exosomes was 
determined by trypan blue exclusion assay and the cells were 
frozen at ‑80˚C for western blot analysis (please see below).
The morphology of the isolated exosomes was further 
characterized by atomic force microscopy using an MFP‑3D 
origin atomic force microscope (AFM; Asylum Research). A 
25 µl aliquot was dropped on amine‑functionalized (3‑amino-
propyl) trimethoxysilane (APTMS) glass cover slips and dried 
in air. The cover slips were washed by sonication with water, 
acetone, ethanol and isopropyl alcohol before re‑soaked in an 
ethanol solution of APTMS for 2 h. Conical‑shaped silicon 
AFM probes with Al reflex coating (k=42 N/m) were mounted 
on the cantilever holder and operated in AC mode. AFM 
data were processed using MFP3D software written in an 
IgorPro environment (Wavemetrics). Exosome dimensions on 
the digitized images were quantified using ImageJ software 
(https://imagej.nih.gov/ij/).
Treatment of cells with exosomes. RWPE‑1 cells were seeded in 
6‑well plates at a density of 0.5x106 cells per well and incubated 
at 37˚C for settlement and growth for 24 h. Either 5 or 50 µg 
of LNCaP or 50 µg RWPE‑1 exosomes (as a negative control), 
corresponded to 1.5x106 and 15.0x106 exosome‑producing 
cells, respectively. The cells were incubated at 37˚C for 24 h, 
washed twice in PBS following the removal of the supernatant, 
and collected by either scraping or trypsinization followed by 
mild centrifugation at 2,600 x g for 10 min at 4˚C. Cell pellets 
were snap‑frozen in liquid nitrogen to preserve RNA and 
protein integrity and were stored short term at ‑80˚C. Scraped 
and trypsinized cells were used for analysis by western blot 
analysis and reverse transcription‑quantitative polymerase 
chain reaction (RT‑qPCR), respectively (please see below).
Western blot analysis. Western blot analysis was performed on 
both the cultured cells and the exosomes derived therefrom. 
Protein lysates were generated on ice in lysis buffer: 25 mM 
Tris, 8 mM MgCl2, 1 mM DTT, 15% glycerol, 1% Triton X‑100 
and protease inhibitor cocktail (Sigma). Insoluble material 
was removed by centrifugation of the lysates at 20,000 x g 
for 10 min at 4˚C. The protein concentration was determined 
by Bradford assay (Sigma) against a bovine serum albumin 
(BSA) standard. In total, 80 µg (for cell lysates) or 20 µg 
(for exosomal lysates) total protein were size‑separated by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS‑PAGE) and electro‑transferred onto polyvinylidene 
(PVDF) membranes. The membranes were stained with 
Figure 1. Representative consecutive sections of normal (disease‑free) and cancerous (stage II, Gleason score of 5) human prostate tissues from a human tissue 
microarray utilized in quantitative immunofluorescence. The sections are approximately 5 µm apart from each other, which allows to analyze near‑identical 
areas for the expression of different markers (CD9, EGR‑1 and FASN), indicated by the dashed circles. Images were acquired by phase contrast light micros-
copy. EGR‑1, early growth response 1; FASN, fatty acid synthase.
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0.1% Ponceau S [3‑hydroxy‑4‑(2‑sulfo‑4‑[4‑sulfophenylazo]
phenylazo)‑2,7‑naphthalenedisulfonic acid; Sigma] in 
5% acetic acid for 5 min at room temperature to visualize 
the blotted proteins. Following 2 brief washes in TBS, the 
membranes were blocked with 5% milk powder in TBS 
containing 0.05% Tween‑20 (TBST) and probed overnight 
at 4˚C with the anti‑CD9, anti‑EGR‑1 and anti‑FASN anti-
bodies listed above in the ‘Immunofluorescence’ paragraph, 
and with anti‑androgen receptor (AR) antibody (sc‑816; AR 
(N‑20), Santa Cruz Biotechnology), and with anti‑β‑actin 
antibody (A1978, Sigma) (for cell extracts) and anti‑actin 
antibody (A3853, Sigma) (for exosomes extracts) at typical 
concentrations of 0.2 µg/ml in TBST. The detection and 
chemiluminescent visualization (Clarity ECL Substrate, 
Bio‑Rad) of target proteins was performed using secondary 
horseradish peroxidase‑conjugated goat anti‑mouse (A0168; 
Sigma) and goat anti‑rabbit (A0546; Sigma) antibodies used 
at 1:15,000 dilutions for 1 h at room temperature. Band inten-
sity (expression level) was quantified by densitometry using 
ImageJ software (https://imagej.nih.gov/ij/).
RT‑qPCR. RNA was isolated using spin column chromatog-
raphy (Qiagen). In total, 1‑3 µg of RNA was transcribed into 
cDNA using random decamers of the Retroscript RT kit (Life 
Technologies; Thermo Fisher Scientific). mRNA expression 
was quantitated in a CFX Connect Real Time PCR Detection 
System from Bio‑Rad using the SYBR‑Green PCR Master 
Mix and SYBR‑Green RT‑PCR Reagents kit (Life 
Technologies; Thermo Fisher Scientific) in 25 µl reactions, 
using 100 ng of template cDNA and a final primer concentra-
tion of 900 nM. The cycling parameters were 95˚C for 5 min 
followed by 45 cycles of 94˚C for 15 sec and 60˚C for 1 min. 
Primers were designed using Primer Express software 
(Invitrogen; Thermo Fisher Scientific) and synthesized by 
Integrated DNA Technologies. The following primer sequences 
(5' to 3') were used: EGR‑1 forward, GAGCAGCCCTAC 
GAGCAC and reverse, AGCGGCCAGTATAGGTGATG; 
FASN forward, AGAACTTGCAGGAGTTCTGGGACA and 
reverse, TCCGAAGAAGGAGGCATCAAACCT; TATA 
binding protein (TBP) forward, CACGAACCACGGCAC 
TGATT and TBP reverse, TTTTCTTGCTGCCAGTCTGGAC. 
RT‑qPCR reactions were performed in triplicate. Relative 
expression levels were determined by the ΔΔCq method (22) 
using TBP as the normalization control after determining that 
amplification efficiencies were similar to the ones of the 
control transcripts.
Statistical analysis. CD9, EGR‑1 and FASN expression levels 
are represented by signal intensities (sum pixel count per 
area) generated by quantitative immunofluorescence analysis 
(as described above). Simple, yet straightforward statistical 
methods were applied to the datasets using the Microsoft 
Office Excel software package. Due to our previously observed 
and well‑known intra‑ and inter‑specimen heterogeneity in 
tissue expression studies (7,10,11), the datasets were inclusive, 
i.e., all available informative images were utilized, and no 
computational calculation was used to identify potential 
outliers. The infinite variance due to tissue heterogeneity is 
Figure 2. Immunostaining with control IgG (for background/absent staining), 
anti‑CD9, anti‑EGR‑1 and anti‑FASN antibodies in human non‑cancerous 
RWPE‑1 (A‑D) and cancerous LNCaP (E‑H) prostate cells. Images illustrate 
fluorescence detected with Alexa Fluor 594 (red; excitation at 590 nm, emis-
sion at 618 nm). The smaller insets illustrate the same image (size reduced) 
and stained with nuclear DAPI (blue) for single cell identification. Scale bars 
(white bars) in all images represent 10 µm. EGR‑1, early growth response 1; 
FASN, fatty acid synthase.
Figure 3. Representative detection of CD9, EGR‑1 and FASN by immu-
nofluorescence in disease‑free (DF; A, D and G), tumor‑adjacent (ADJ; 
B, E and H), and tumor (TUM; C, F and I) human prostate tissues. Images 
illustrate fluorescence detected with Alexa Fluor 594 (red; excitation at 
590 nm, emission at 618 nm). The smaller insets illustrate the same image 
(size reduced) and stained with nuclear DAPI (blue) for single cell identifica-
tion. Scale bars (white bars) in all images represent 10 µm. EGR‑1, early 
growth response 1; FASN, fatty acid synthase.
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expressed as the coefficient of variation in % in the text of the 
‘Results’ section. Single factor analysis of variance (ANOVA) 
was used to compare multiple datasets with unequal variances. 
The post hoc Fishers' least significant difference (LSD) test 
was used to determine the significance of the difference 
between the means of the datasets. ANOVA followed by LSD 
was also used to analyze the results of western blot analysis 
and RT‑qPCR. Statistical significance in these comparisons of 
the means was defined as P≤0.05. The datasets were mined for 
potential associations between CD9 and EGR‑1 and between 
CD9 and FASN by determining the Pearson's correlation 
coefficient r. The significance for these observations was 
determined by first calculating the t‑value of the correlation 
using the equation t=r/SQRT(1‑r2/n‑2), where ‘r’ is the 
correlation coefficient, ‘n’ is the number of samples, and ‘2’ is 
the degree of freedom. The t‑value was then used to determine 
the significance of ‘r’ by the two‑tailed Student t‑distribution 
(TDIST; statistical significance defined as P≤0.05).
Results
Detection of CD9, EGR‑1 and FASN expression in human 
prostate cells and tissues. The antibodies used to detect CD9, 
EGR‑1 and FASN by immunofluorescence in human tissues 
were first tested in the human non‑cancerous RWPE‑1 and in 
the cancerous LNCaP cell models, which allowed the illustra-
tion of the specificity of the antibodies. As shown in Fig. 2, 
CD9 staining was primarily evident for the cell surface, while 
staining for FASN was primarily cytoplasmic for both cell 
models, as expected. EGR‑1 staining seemed to be somewhat 
more diffuse, in agreement with its reported possible local-
ization in both the nucleus and the cytoplasm, depending on 
cellular type and context (11,23). In addition, the expression 
level for all three markers was slightly higher in the LNCaP 
than in the RWPE‑1 cells. Important for the use of the anti-
bodies in human tissues, the isotype‑matched unspecific 
control antibody resulted in minimal, if any, staining in both 
cell types.
The same antibodies and staining conditions were used to 
detect CD9, EGR‑1 and FASN in human prostate tissues of 
the cancerous type, histologically normal tumor‑adjacent, as 
well as disease‑free specimens, as outlined in Table I. Due to 
the higher complexity of human tissues compared to cultured 
cells, the staining for all three protein markers was somewhat 
more diffuse, but nevertheless typical for the corresponding 
target, as shown in Fig. 3. A total of 336 digitized confocal 
images from 22 individual specimens were used for the quan-
tification of signal intensity (expression) by computational 
detection of sum pixel count per area. The coefficients of 
variation ranges for CD9, EGR‑1 and FASN expression were 
14.5‑17.7, 16.1‑27.1 and 15.0‑21.3%, respectively (data not 
shown). These are consistent with previous findings by the 
authors (7,10,11) and generally indicate the well‑known intra‑ 
and inter‑tissue heterogeneity of expression. To acknowledge 
this heterogeneity, an inclusive approach was adopted, i.e., any 
computational determination of potential outliers was deemed 
unjustified, and all available images of sufficient quality were 
included for the analysis of expression. Group comparisons 
by ANOVA revealed significant differences between the 
types of tissues for all three markers (P<0.01). As shown in 
Fig. 4A, CD9 mean expression was slightly, yet significantly 
higher in tumor (1.1x) and in tumor‑adjacent (1.2x) compared 
to disease‑free tissues (P<0.01), while it was similar between 
tumor and tumor‑adjacent tissues (P>0.05). Similarly, as 
shown in Fig. 4B, EGR‑1 mean expression in tumor (1.3x) and 
tumor‑adjacent (1.5x) tissues was slightly, yet significantly 
elevated compared to disease‑free tissues (P<0.01), while it was 
similar between tumor and tumor‑adjacent tissues (P>0.05). 
Finally, the same mean expression pattern was observed for 
FASN (Fig. 4C), with expression levels in tumor (1.2x) and 
tumor‑adjacent (1.1x) being slightly, yet significantly higher 
than in disease‑free tissues (P<0.01) and similar between 
tumor and tumor‑adjacent tissues (P>0.05). Taken together, 
these results corroborate the field cancerized nature of tissues 
adjacent to prostate adenocarcinomas.
Correlation between CD9, EGR‑1 and FASN expression 
in human prostate tissues. In a previous study, the authors 
Figure 4. Relative expression of (A) CD9, (B) EGR‑1, and (C) FASN in 
disease‑free (DF), tumor‑adjacent (ADJ) and tumor (TUM) human prostate 
tissues. The whisker plots/boxes represent group means (middle line) and 
quartiles (25th and 75th percentiles) at their ends; lines above and below 
boxes indicate the 10th and the 90th percentiles, respectively. The indicated 
P‑values denote the level of statistical significance for the differences between 
groups, as calculated by single factor ANOVA. *P≤0.05, significant differ-
ence in means compared to DF tissues; #P>0.05, no significant difference in 
means between the ADJ and TUM groups. EGR‑1, early growth response 1; 
FASN, fatty acid synthase.
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reported on the correlation between EGR‑1 and other field 
cancerization markers, i.e., platelet‑derived growth factor A 
(PDGF‑A), macrophage inhibitory cytokine 1 (MIC‑1) and 
FASN (7), with the question in mind of whether EGR‑1, as a 
master transcription factor, could be a regulator of the other 
three factors. Similarly, one major objective of the present 
study was to explore the possibility that exosomes are effectors 
of field cancerization in prostate tissues. Thus, this study aimed 
to determine a potential association between the occurrence 
of CD9 and EGR‑1, and between CD9 and FASN within the 
individual types of tissues analyzed in this study, and at deter-
mining whether such a correlation changes in these different 
types of tissues. This was possible by generating images at the 
same position on the TMAs that were consecutive sections 
approximately 5 µm apart from each other, as shown in 
Fig. 1. Correlations between CD9 and EGR‑1, and between 
CD9 and FASN were determined by Pearson's correlation 
analysis, which is by default amenable to both positive and 
negative correlations. Of particular interest was to determine 
whether possible correlations differ between different types 
of tissues, i.e., disease‑free, tumor‑adjacent and tumor tissues. 
Pearson's correlations between CD9 and EGR‑1 were r=0.44 
(P<0.05), r=0.73 (P<0.01) and r=0.17 (P=0.32) in disease‑free, 
tumor‑adjacent and tumor tissues, respectively (Fig. 5A‑C). 
Pearson's correlations between CD9 and FASN were r=0.57 
(P<0.01), r=0.59 (P<0.01) and r=0.54 (P<0.01) in disease‑free, 
tumor‑adjacent and tumor tissues, respectively (Fig. 5D‑F). 
The strongest correlations between CD9 and EGR‑1, and 
between CD9 and FASN were thus observed in tumor‑adjacent 
tissues. Given the rather high level of heterogeneity, these 
values were deemed to be markedly high. Since CD9 expres-
sion represents exosome formation and excretion (24‑26) and 
EGR‑1 is a marker of field cancerization (7,11), these results 
suggest a potential role of exosomes in the formation of field 
cancerization.
Effect of exosomes from cancerous cells on non‑cancerous 
cells. The potential of exosomes derived from cancer cells to 
induce the expression of field cancerization markers, such as 
EGR‑1 and FASN in non‑cancerous cells was experimentally 
examined using the non‑cancerous RWPE‑1 and the cancerous 
LNCaP cell models. The golden standard method was used, 
i.e., ultracentrifugation, to isolate exosomes from LNCaP and 
RWPE‑1 cells and determined their protein concentration. 
Consistently, it was calculated that 1 µg exosomal protein 
was produced by approximately 300,000 cells under standard 
growth conditions during 24 h of culture. Atomic force micro-
scopic analysis of the LNCaP and RWPE‑1 exosomes (Fig. 6) 
revealed horizontal and vertical dimensions of 74.6±26.2 and 
78.0±28.4 nm for the LNCaP cells (Fig. 6A), and 89.6±31.4 
and 93.6±34.0 nm for the RWPE‑1 cells (Fig. 6B), respectively. 
This size is in agreement with that of numerous previous reports 
on exosomes from cells of prostatic origin (17‑20). LNCaP 
and RWPE‑1 exosomes were also analyzed biochemically 
by western blot analysis, along with the corresponding cells 
that secreted them (Fig. 7). Immunodetection using specific 
antibodies revealed the presence of CD9 in both exosomes 
and cells. In accordance with previously reported proteomic 
profiles of exosomes secreted by prostate cells (24), actin and 
FASN were also detected in both LNCaP cells and exosomes, 
although FASN expression was under the detection limit for 
RWPE‑1 cells. However, another study did not report the pres-
ence of FASN in LNCaP exosomes, but instead reported the 
presence of AR (26), which we did not find in either cell types. 
These discrepancies may be due to different culture conditions, 
collection times, and other experimental and/or analytical 
parameters. EGR‑1 was detected in the cellular extracts, 
but not in the exosomal lysates, which is congruent with its 
absence in the previously reported proteomic profiles (24,26). 
Finally, the AR was expressed in LNCaP cells, but was virtu-
ally absent in RWPE‑1 cells if not induced by excess androgen 
as reported (ATCC) (Fig. 7).
To examine the effect of prostate cancer cell‑derived 
exosomes on the expression of the two field cancerization 
markers EGR‑1 and FASN in non‑cancerous prostate cells, the 
RWPE‑1 cells were treated with LNCaP‑derived exosomes at 
a 3:1 and 30:1 cell‑to‑cell ratio for 16 h. The protein profiles 
of the lysates of the treated RWPE‑1 cells did not appear to 
be different from the control, suggesting that the exosomes 
did not induce major expressional changes (data not shown). 
Western blot analysis revealed an inducive effect of up to 
3.5‑fold, for EGR‑1, but only up to 1.5‑fold for FASN (Fig. 8). 
FASN protein has previously been demonstrated to be part 
Figure 5. Correlation analysis between CD9 and (A‑C) EGR‑1 and between 
(D‑F) CD9 and FASN in disease‑free (DF), tumor‑adjacent (ADJ) and 
tumor (TUM) human prostate tissues. The x‑ and y‑axes of the scatter plots 
represent relative expression in units of fluorescence, as calculated by the 
NIS‑Elements AR 4.30.02/64bit software. Each dot represents a measure-
ment data point and the dotted line represents the best fit of correlation. 
‘r’ denotes the Pearson's correlation. The P‑value denotes the significance 
for the Pearson's correlation based on the t‑value of the correlation and the 
two‑tailed Student t‑distribution. Statistical significance is defined as P≤0.05. 
EGR‑1, early growth response 1; FASN, fatty acid synthase.
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of the exosomal content released by prostate cells (24). Thus, 
in order to demonstrate that a possible inducive expression 
was due to transcriptional activation, the induction of FASN 
mRNA was measured by RT‑qPCR. At lower concentra-
tions of exosomes, FASN mRNA transcription was induced 
approximately 10‑fold. Similarly, EGR‑1 mRNA was induced 
approximately 8‑fold (Fig. 9). Overall, these results are in 
good agreement with the observations made in the tissues and 
suggest a regulatory association between exosome release and 
FASN and EGR‑1 expression in human prostate tissues.
Discussion
Several reviews of molecular pathology known as field cancer-
ization, or the field effect, have emphasized its potential to 
improve the clinical management of solid tumors, including 
Figure 7. Detection of CD9, FASN, AR, EGR‑1 and actin in LNCaP and RWPE‑1 cells (represented by ‘C’) and exosomes (represented by ‘E’) by western blot 
analysis/chemiluminescence. The standard marker and the protein profiles are stained with Ponceau S dye. EGR‑1, early growth response 1; FASN, fatty acid 
synthase.
Figure 6. Characterization of cancerous (A) LNCaP and non‑cancerous (B) RWPE‑1 prostate cell‑derived exosomes. The left panels illustrate the atomic force 
microscopic image of exosomes. The distances (in μm) are indicated on the x‑ and y‑axes. The grey scale bars on the right indicate the height of the particles. 
The right panels illustrate the horizontal and vertical size distribution (in nm) of the particles. The whisker plots/boxes represent group means (middle line) 
and quartiles (25th and 75th percentiles) at their ends; lines above and below boxes indicate the 10th and the 90th percentiles, respectively. EGR‑1, early growth 
response 1; FASN, fatty acid synthase.
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prostate cancer (6,13,14,27). In this regard, it is conceivable that 
the molecular aberrations, be it of genetic, epigenetic and/or 
biochemical nature, could act as biomarkers along the entire 
development of the disease and/or as molecular targets for 
preventative or interventive therapy. The authors have previ-
ously contributed to the identification of markers of prostate 
field cancerization and have reported on their potential clinical 
uses, thereby validating some of them (7‑13). Accordingly, the 
authors have previously reported on two recurrent markers of 
field cancerization, i.e., the key transcription factor and master 
regulator, EGR‑1, and the lipogenic enzyme, FASN, specifi-
cally their upregulation at the protein level in histologically 
normal tissue adjacent to prostate tumors when compared to 
disease‑free, truly normal prostatic tissues (7,8,11). It is not 
inconceivable that such molecular aberrations could be used 
for example, to improve the diagnosis of prostate cancer in 
false‑negative biopsies (13). The latter continue to challenge 
confirmatory diagnoses of prostate adenocarcinoma following 
an abnormal prostate‑specific antigen (PSA) test or suspicious 
digital rectal examination (DRE) (28‑31). In this scenario, 
tissue affected by field cancerization increases the clinically 
informative area under microscopic analysis by the surgical 
pathologist when combined with immunological techniques. 
This could lead to a reduction of repeat biopsies and thus, a 
more effective clinical management. The possibility to predict 
the existence of lesions in a tissue without their visual detection 
has prompted others to call tissues affected by field canceriza-
tion ‘TINT’, for ‘tumor indicating normal tissue’ (32). Even 
in the case of a positive detection of cancerous tissue in biop-
sies, markers of field cancerization could have a meaningful 
application. The clinical setting referred to here is active 
surveillance, which is increasingly chosen by patients diag-
nosed with low‑risk prostate cancer, defined as low number 
of positive biopsy cores, low % of tissue affected and low 
Gleason grade (33, 34). Active surveillance programs are 
meant to defer more aggressive treatments of curative intent 
but with quality of life lowering side effects, including radical 
prostatectomy (35,36). These programs include frequent PSA 
testing and the histological examination of repeat biopsies 
to monitor potential cancer progression. It is thus conceiv-
able that well‑defined areas, markers and parameters of field 
cancerization could be monitored during this time. Similarly, 
the effect of neoadjuvant therapeutic interventions could be 
assessed during this pre‑surgical setting (13,37). The extent 
Figure 9. Effect of LNCaP prostate cancer cell‑derived exosomes on 
non‑cancerous RWPE‑1 prostate cells. Relative mRNA expression of FASN 
and EGR‑1 in RWPE‑1 cells treated with LNCaP‑derived or RWPE‑1‑derived 
exosomes (control). Bars show the average of 3 independent experiments 
[± standard error (SE)]. Control is set to 1.0 and FASN and EGR‑1 are com-
pared to the control. *P≤0.05, statistical significance compared to the control. 
EGR‑1, early growth response 1; FASN, fatty acid synthase.
Figure 8. Effect of LNCaP prostate cancer cell‑derived exosomes (5 or 50 µg) on non‑cancerous RWPE‑1 prostate cells. The top panel illustrates relative 
protein expression of FASN and EGR‑1 in RWPE‑1 cells treated with LNCaP‑derived exosomes (Exo) or with 50 µg exosomes from non‑cancerous RWPE‑1 
cells (control). β‑actin was used as a protein loading control. The bottom panel illustrates the quantification of chemiluminescent detection of FASN and EGR‑1 
by densitometry (ImageJ software). Bars show the average of 3 independent experiments [± standard error (SE)] and represent the ratio of FASN and EGR‑1 
with β‑actin signal (control) set to 1.0 and FASN and EGR‑1 compared to RWPE‑1 exosome control. *P≤0.05, statistical significance compared to the control. 
EGR‑1, early growth response 1; FASN, fatty acid synthase.
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of field cancerization could also be indicative of a positive 
surgical margin, which is an important clinical parameter in 
the administration of focal therapy, a less invasive therapeutic 
modality on the rise (13,38). In this scenario, the presence of a 
field effect at the margin may be indicative of an elevated risk 
for progression or of the extent of tumor multifocality within 
the prostate (39). Lastly, given the widely accepted premise 
that the observed molecular aberrations in histologically 
normal tissues constitute a state of pre‑malignancy, markers 
of field cancerization could represent targets for therapeutic 
intervention (13,32).
Regardless of the potential clinical application, it 
is widely accepted that the molecular etiology of field 
cancerization should be understood in order to fully benefit 
from it. It is thus important to identify the distinct cellular 
and molecular mechanisms and pathways that result in the 
molecular aberrations observed in tissues affected by a field 
effect. For example, for the afore‑mentioned protein factors 
EGR‑1 and FASN, the events that lead to their upregulation 
in histologically normal tissues adjacent to existing prostate 
tumors remain unknown. Thus, it would be of interest to 
determine the mechanisms through which a prostate tumor 
lesion influences its surrounding tissues, thereby potentially 
priming it for the induction of multifocal disease. As is 
well‑known from 2019, the role of exosomes in cell‑to‑cell 
and in tissue‑to‑tissue communication has been established 
and proven to be a major mode of physiological and 
reciprocal interactions in multicellular organisms (15,16). 
While studies of exosomes of prostatic origin tend to focus 
on their application as biomarkers in liquid biopsy schemes 
and on the molecular characterization of their content (17‑20), 
reports on specific exosomal factors on the genotype and 
phenotype of recipient cells are now increasing in number. 
For example, prostate cancer cell‑derived exosomes have 
been shown to inhibit and promote osteoclast and osteoblast 
cell activity, respectively (40,41), which could promote the 
overall osteoblastic phenotype of prostate cancer metastases. 
Exosomes shed by prostate cancer cells have been shown 
to carry integrin αvβ3 which, when deposited in recipient 
cells, is postulated to increase their motility (42). Similarly, 
the motility of stromal cells has been shown to increase by 
prostate cancer exosomes (43). Hypoxia‑induced exosomes 
lead to increased prostate cell survival and invasiveness by 
targeting molecules of the adherens junctions (44,45), while 
the exosomal factor and tetraspanin CD9 promotes prostate 
cancer cell growth under androgen‑deprived conditions (46). 
Based on such reports, the existence of a new link has been 
hypothesized between cancer cell‑derived exosomes and the 
induction of field cancerization. Accordingly, the present 
study attempted for the first time, at least to the best of our 
knowledge, to demonstrate a quantitative association between 
the exosomal marker, CD9, and our previously identified 
markers of field effect, EGR‑1 and FASN. This study on a 
pilot tissue cohort indicates a positive correlation between 
CD9 expression on one side and EGR‑1 and FASN expression 
on the other, with the link with the former factor being more 
significant. The authors have previously demonstrated that 
these two factors are upregulated in prostate tissues resected 
1 cm from the visible tumor margin at both the mRNA 
and protein level (7,8,11). The induction of both factors in 
histologically normal areas of the prostate by tumor‑derived 
exosomes is congruent with our hypothesis of a ‘priming’, 
potentially tumor‑promoting effect. EGR‑1 is a central 
transcription regulator of a number of molecular pathways 
and acts divergently according to the cell context (23,47,48). 
However, in prostate tumors it acts as a promoter of cancer 
progression (47,49,50). FASN is equally established in 
prostate cancer and has been termed a metabolic oncogene. It 
promotes tumor cell proliferation through lipid biosynthesis 
and the post‑translational modification of proteins and is 
the focus of ongoing efforts to develop specific inhibitors 
of its enzymatic activity (51, 52). Of note, the authors have 
previously demonstrated a potential regulatory function of 
EGR‑1 for FASN expression (7). Overall, the data presented 
in this report corroborates in an independent tissue cohort 
and data set that EGR‑1 and FASN are recurrent markers 
of prostate field cancerization. Of note, the magnitude of 
the overexpression of EGR‑1 and FASN in field cancerized 
prostate tissues can vary in independent studies due to tissue 
heterogeneity and to the type of antibodies used. Of note 
however, the present study independently corroborates the 
previous findings by the authors (7,10,11). In addition, for both 
factors, future studies are required to include testing whether 
their transcriptional and enzymatic activities, respectively, 
are also heightened in field cancerized tissues. As a novel 
observation, the data of the present study demonstrate that 
CD9 expression contributes similarly to this phenomenon 
through its change (increase) from disease‑free to 
tumor‑adjacent and to histologically cancerous tissues. The 
authors acknowledge the possibility that the observed CD9 
staining in the tissues can be due to its documented expression 
in prostate gland epithelial cells (proteinatlas.org). Since CD9 
is also a proven exosomal marker (24), it is not inconceivable 
that the observed expression is representative of exosomal 
release. However, the findings of this study need to be 
corroborated in follow‑up studies using additional exosomal 
markers, including for example CD63 (53). Importantly, 
the results of this study support the notion that exosomes 
released by cancerous lesions in the prostate could induce 
the upregulation of factors that promote the biochemical 
transformation of physiologically and phenotypically normal 
cells, leading to the formation of molecularly altered fields. 
For EGR‑1, the data of this study are congruent with those 
of other studies in other cell systems, where exosomes exert 
their actions through EGR‑1 expression and activation, for 
example in muscle cells affected by exosomes released by 
adipose cells (54).
For the most part, in this study, the in vitro data using the 
LNCaP and the RWPE‑1 cell models support the associations 
made in situ in human tissues, although the link between CD9 
(exosomes) and EGR‑1 (field effect) is clearer. With respect 
to FASN, this study prompts for caution when comparing 
observations made in tissues with those made in cell models. 
This is due to the fact that FASN may be part of the ‘cargo’ 
of exosomes released by prostate cancer cells, although 
conflicting results exist (24,26). Of note, the results of this 
study support the those of the study by Duijvesz et al (24). 
Thus, an elevated FASN expression in field cancerization may 
be, at least in part, directly due to exosomal FASN delivery. 
The in vitro experiments of this study, however, indicate de 
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novo induction of FASN mRNA, which, for the most part, 
is accompanied by corresponding protein levels. The FASN 
experiments performed herein warrant further investiga-
tions using functional approaches in systems that reflect the 
complexity of human tissues. The same may be true for the 
AR, the presence of which in prostate exosomes is equally 
inconclusive (24,26). It is known that in cultured cells, the 
physiological complexity is relatively low and may not reflect 
entirely the complex regulatory networks at work in tissues. 
With respect to the latter, it can be argued that tissue studies 
are static and compromised by sample heterogeneity. However, 
they are also physiologically relevant and better reflect the 
complexity of cellular and molecular pathways influenced by 
the environment, for example in animal models. Importantly, 
it is demonstrated herein that when coupled with sophisticated 
and quantitative data acquisition methods, they can deliver 
meaningful indications of molecular associations in a physi-
ologically relevant in situ environment, even in the presence 
of high heterogeneity. As it is widely accepted that field effect 
represents a pre‑malignant state, such knowledge may aid in 
the development of targeted intervention strategies preventing 
progression of pre‑malignancy to cancer.
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